<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of stage II seminoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of stage II seminoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of stage II seminoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Leslie Ballas, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Darren Feldman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Timothy D Gilligan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Germ cell tumors (GCTs) account for most testicular cancers. The most common histologic subtypes of GCTs are nonseminomatous and seminomatous (ie, seminomas) tumors. Stage II seminomas are a highly curable malignancy. (See  <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors"</a>.)</p><p>The initial treatment of patients with a clinically confirmed diagnosis of stage II seminoma will be presented here. The clinical presentation, diagnosis, and staging of testicular cancer and the treatment of stage I seminoma are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2993.html" rel="external">"Treatment of stage I seminoma"</a>.)</p><p></p><p class="headingAnchor" id="H2451196033"><span class="h1">DEFINITION OF STAGE II SEMINOMA</span><span class="headingEndMark"> — </span>Patients with clinical stage II seminoma have the presence of pure seminoma in their orchiectomy specimen and imaging studies of the abdomen and pelvis that suggest the disease is limited to the regional (ie, retroperitoneal) lymph nodes  (<a class="graphic graphic_table graphicRef110731 graphicRef110732" href="/z/d/graphic/110731.html" rel="external">table 1A-B</a>). Per the American Joint Committee on Cancer (AJCC) staging guidelines, potentially involved regional lymph nodes measure at least 1 cm in greatest dimension (ie, on the long axis of cross-sectional imaging). However, repeat imaging and clinical judgment are necessary to determine if these lymph nodes are benign or malignant. (See <a class="local">'Borderline lymph nodes (1 cm)'</a> below.)</p><p>Imaging studies should otherwise demonstrate no evidence of metastatic disease at other distant sites, such as the lungs, thoracic or pelvic lymph nodes, liver, or central nervous system. Approximately 15 percent of all patients initially diagnosed with seminoma present with stage II disease [<a href="#rid1">1</a>]. Further details on the initial diagnostic evaluation of seminoma are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors", section on 'Diagnostic evaluation'</a>.)</p><p>Stage II seminomas are further classified into clinical stage IIA, IIB, or IIC disease using the AJCC eighth edition staging system for testicular cancer  (<a class="graphic graphic_table graphicRef110731 graphicRef110732" href="/z/d/graphic/110731.html" rel="external">table 1A-B</a>). Disease stage is one of the clinical factors used to select therapy. (See <a class="local">'Treatment'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage IIA seminoma</strong> – Any or unknown pathologic tumor (T) stage <strong>and</strong> clinical N1 disease (metastasis with a lymph node mass ≤2 cm in greatest dimension <strong>or</strong> multiple lymph nodes, all of which are ≤2 cm in greatest dimension)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage IIB seminoma</strong> – Any or unknown pathologic T stage <strong>and</strong> clinical N2 disease (metastasis with a lymph node mass &gt;2 cm and ≤5 cm in greatest dimension <strong>or</strong> multiple lymph nodes, with any one mass &gt;2 cm but ≤5 cm in greatest dimension).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A stage IIB seminoma is further subclassified as "non-bulky" if the regional lymph node(s) are ≤3 cm. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage IIC seminoma</strong> – Any or unknown pathologic T stage <strong>and</strong> clinical N3 disease (metastases with a lymph nodes mass &gt;5 cm in greatest dimension). </p><p></p><p>Tumor marker studies are obtained postorchiectomy as part of staging to determine serum marker (S) status  (<a class="graphic graphic_table graphicRef110731 graphicRef110732" href="/z/d/graphic/110731.html" rel="external">table 1A-B</a>). These tumor markers include lactate dehydrogenase (LDH), alpha-fetoprotein (AFP), and beta-human chorionic gonadotropin (beta-hCG). The most important posttreatment tumor marker in pure seminomas is beta-hCG since an elevated LDH is not always specific to testicular cancer, and seminomas do not, by definition, produce AFP.</p><p>In stage II seminomas, postorchiectomy tumor markers can either be within normal limits (ie, S0) or elevated within a specific range (S1; defined as LDH less than 1.5 times the upper limit of normal <strong>and</strong> beta-hCG less than 5000 mIU/mL <strong>and</strong> AFP less than 1000 ng/mL). (See  <a class="medical medical_review" href="/z/d/html/2995.html" rel="external">"Serum tumor markers in testicular germ cell tumors"</a>.)</p><p>Patients with stage II seminoma and a mild elevation of either LDH OR beta-hCG alone do not meet criteria for S1 disease and are typically treated using a similar approach to those with S0 disease. Such patients may also be evaluated for alternative causes of the isolated tumor marker. (See  <a class="medical medical_review" href="/z/d/html/2995.html" rel="external">"Serum tumor markers in testicular germ cell tumors", section on 'Lactate dehydrogenase'</a> and  <a class="medical medical_review" href="/z/d/html/2995.html" rel="external">"Serum tumor markers in testicular germ cell tumors", section on 'False-positive hCG'</a>.)</p><p>Tumors with postorchiectomy markers studies that are higher than these levels (S2 or S3 disease) or are not available/performed (SX) are classified as advanced GCTs, and their management is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors"</a>.)</p><p class="headingAnchor" id="H1671753118"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>For patients with stage II seminoma, treatment options include surveillance, cisplatin-based chemotherapy, and radiation therapy (RT) to the retroperitoneal and iliac lymph nodes  (<a class="graphic graphic_algorithm graphicRef142688" href="/z/d/graphic/142688.html" rel="external">algorithm 1</a>). Selection of therapy is based on disease stage, extent of nodal involvement, and presence or absence of tumor marker elevation after orchiectomy. Since most seminomas can be treated successfully, clinicians must also consider possible long-term treatment-related toxicities when selecting therapy. (See  <a class="medical medical_review" href="/z/d/html/2955.html" rel="external">"Treatment-related toxicity in testicular germ cell tumors"</a> and  <a class="medical medical_review" href="/z/d/html/14236.html" rel="external">"Approach to the care of long-term testicular cancer survivors"</a>.)</p><p>These treatment approaches, which are based upon the clinical practice of the UpToDate contributors, are also generally consistent with guidelines from the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the Canadian Urological Association [<a href="#rid2">2-4</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Stage IIA seminoma (S0)</span></p><p class="headingAnchor" id="H1390151259"><span class="h3">Borderline lymph nodes (1 cm)</span><span class="headingEndMark"> — </span>For patients with clinical stage IIA seminoma (S0) and borderline enlarged retroperitoneal lymph nodes (approximately 1 cm in greatest dimension), we observe for six to eight weeks, then repeat imaging  (<a class="graphic graphic_algorithm graphicRef142688" href="/z/d/graphic/142688.html" rel="external">algorithm 1</a>). In patients with clinical stage II seminoma and lymph nodes slightly larger than 1 cm, the rate of pathologic N0 (pN0) disease at retroperitoneal lymph node dissection (RPLND) is approximately 15 to 30 percent [<a href="#rid4">4,5</a>]. These findings suggest that some lymph nodes may be enlarged due to non-malignant etiologies, and a period of observation could prevent overtreatment in this population.</p><p>Our approach is to repeat the original imaging study used to detect the lymph nodes in six to eight weeks to re-evaluate the size of the lymph nodes. Imaging options include contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen and pelvis. (See  <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors", section on 'Imaging studies'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients whose lymph nodes decrease in size to less than 1 cm are likely benign. Such patients can continue surveillance or be treated like those with stage I seminoma. (See  <a class="medical medical_review" href="/z/d/html/2993.html" rel="external">"Treatment of stage I seminoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients whose lymph nodes increase in size on repeat imaging can be more confidently treated for stage II seminoma. (See <a class="local">'Lymph nodes between 1 and 2 cm'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients whose lymph nodes remain stable in size can continue imaging surveillance, which allows time to determine the etiology of the nodes (benign versus malignant) and the appropriate treatment strategy. </p><p></p><p>Imaging surveillance can help determine the appropriate treatment strategy and avoid over- or under-treatment of borderline lymph nodes. If the nodes are due to metastatic seminoma but the patient is treated for stage I seminoma with adjuvant therapy, this management represents undertreatment and could result in an increased relapse risk. In contrast, if the nodes are benign, but the patient is treated for stage II seminoma, this management represents overtreatment and could result in unnecessary toxicity. </p><p class="headingAnchor" id="H2793467353"><span class="h3">Lymph nodes between 1 and 2 cm</span><span class="headingEndMark"> — </span>For patients with clinical stage IIA seminoma (S0) and enlarged retroperitoneal lymph nodes between 1 cm and 2 cm in greatest dimension, treatment options include either RT or cisplatin-based chemotherapy  (<a class="graphic graphic_algorithm graphicRef142688" href="/z/d/graphic/142688.html" rel="external">algorithm 1</a>). Further details on treatment regimens are discussed below. (See <a class="local">'Treatment modalities'</a> below.)</p><p>Both treatment approaches have similar relapse rates and result in high disease-free survival (90 percent or greater at five years). The optimal treatment has not been established since RT and chemotherapy have not been directly compared in randomized trials. The selection of therapy is based on multiple factors such as patient and clinician preference and experience; lymph node size, number, and distribution; patient convenience; and toxicity. Our approach, including advantages and disadvantages, is as follows: </p><p class="bulletIndent1"><span class="glyph">●</span>Patients with larger (closer to 2 cm) or more numerous lymph nodes (especially those distributed over a large area of the retroperitoneum) may derive greater benefit from chemotherapy over RT, extrapolating from data in more advanced stage tumors. </p><p></p><p class="bulletIndent1">In addition, patients treated with RT who develop relapsed or refractory disease may subsequently require chemotherapy. Such sequential multimodality therapy is associated with a higher risk of subsequent malignancies and cardiovascular disease compared with either modality alone [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/2999.html" rel="external">"Diagnosis and treatment of relapsed and refractory testicular germ cell tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, RT is typically associated with less acute toxicities than cisplatin-based chemotherapy and may be preferable for some patients, particularly those with smaller lymph nodes. RT also has a shorter treatment duration (approximately three weeks) than chemotherapy (between nine and twelve weeks, depending upon the regimen selected). (See  <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">"Radiation therapy techniques in cancer treatment"</a>.)</p><p></p><p>RT and chemotherapy have similar relapse rates for stage IIA seminoma. In a systematic review and meta-analysis of thirteen observational studies, 890 patients with stage II seminoma were treated with either cisplatin-based chemotherapy or RT. Among those with clinical stage IIA seminoma, the pooled relapse rate (RR) was similar between RT (RR 0.05, 95% CI 0.02-0.07) and chemotherapy (RR 0.07, 95% CI 0-0.19) [<a href="#rid7">7</a>]. Similar results have been demonstrated in subsequent observational studies comparing relapse rates for RT and chemotherapy [<a href="#rid8">8</a>]. </p><p>RT and chemotherapy also result in similarly high disease-free survival for stage IIA seminoma. In observational studies, the five-year disease-free survival for RT is approximately 90 percent or greater [<a href="#rid4">4,7-11</a>], which is similarly high for chemotherapy [<a href="#rid12">12</a>]. As an example, chemotherapy (four cycles of <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> [EP] or three cycles of <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> plus etoposide plus cisplatin [BEP]) was evaluated in 72 patients with stage IIA or IIB seminoma in a trial from the Spanish Germ Cell Cancer Group [<a href="#rid12">12</a>]. Among the 18 patients with IIA disease, there were no relapses, and the five-year progression-free survival (PFS) was 100 percent. The five-year overall survival rate for the entire study population was 95 percent, with only one death secondary to progressive seminoma.</p><p>Long-term toxicity profiles also differ between RT and chemotherapy and should be discussed with the patient. RT can be associated with the risk of secondary (ie, subsequent) malignancies and gastrointestinal disease, whereas chemotherapy can be associated with secondary malignancies, cardiovascular disease, hypertension, hyperlipidemia and metabolic syndrome, neuropathy, tinnitus, and infertility [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/2955.html" rel="external">"Treatment-related toxicity in testicular germ cell tumors"</a> and  <a class="medical medical_review" href="/z/d/html/14236.html" rel="external">"Approach to the care of long-term testicular cancer survivors"</a>.)</p><p class="headingAnchor" id="H3162645579"><span class="h2">Stage IIA seminoma (S1)</span><span class="headingEndMark"> — </span>We offer cisplatin-based chemotherapy to patients with clinical stage IIA seminoma and S1 disease  (<a class="graphic graphic_algorithm graphicRef142688" href="/z/d/graphic/142688.html" rel="external">algorithm 1</a>). Such patients have persistently elevated or rising tumor markers within a specific range, particularly serum beta-HCG levels, postorchiectomy  (<a class="graphic graphic_table graphicRef110731 graphicRef110732" href="/z/d/graphic/110731.html" rel="external">table 1A-B</a>). These tumors, which are classified as "good-risk" disease using the International Germ Cell Consensus Classification criteria  (<a class="graphic graphic_table graphicRef61906" href="/z/d/graphic/61906.html" rel="external">table 2</a>), are treated with either four cycles of EP  (<a class="graphic graphic_table graphicRef63222" href="/z/d/graphic/63222.html" rel="external">table 3</a>) or three cycles of BEP  (<a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">table 4</a>). </p><p>Further details and data for this risk-stratified approach in advanced testicular germ cell tumors (GCTs) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'General approach to advanced disease'</a>.)</p><p class="headingAnchor" id="H1483356983"><span class="h2">Stage IIB seminoma (S0)</span><span class="headingEndMark"> — </span>For most patients with clinical stage IIB seminoma (S0), we suggest cisplatin-based combination chemotherapy rather than RT  (<a class="graphic graphic_algorithm graphicRef142688" href="/z/d/graphic/142688.html" rel="external">algorithm 1</a>). Chemotherapy has high overall survival rates (95 percent or greater), and observational studies suggest a lower risk of relapse with chemotherapy compared with RT. For patients with non-bulky stage IIB disease (lymph nodes ≤3 cm) and S0 disease, RT is an appropriate alternative to chemotherapy. </p><p>In a systematic review and meta-analysis of thirteen observational studies, 890 patients with stage II seminoma were treated with either cisplatin-based chemotherapy or RT. Among those with clinical stage IIB seminoma, the pooled relapse rate was 0.05 for chemotherapy (95% CI 0-0.11) and 0.12 for RT (95% CI 0.06-0.17), although this difference was not statistically significant [<a href="#rid7">7</a>]. In another systematic review of observational studies, among patients with stage IIB seminoma, the range of relapse rates was 0 to 14 percent for those receiving chemotherapy versus 10 to 21 percent for those treated with RT [<a href="#rid8">8</a>]. </p><p>Long-term survival outcomes for chemotherapy were evaluated in a trial from the Spanish Germ Cell Cancer group [<a href="#rid12">12</a>]. In this study, 72 patients with stage IIA or IIB seminoma received either four cycles of EP or three cycles of BEP. Among the 54 patients with IIB disease, relapses were seen in six patients (11 percent), and the five-year PFS was 87 percent. The overall survival rate at five years was 95 percent, with only one death secondary to progressive seminoma. </p><p class="headingAnchor" id="H2903552709"><span class="h2">Stage IIB seminoma (S1)</span><span class="headingEndMark"> — </span>We offer cisplatin-based chemotherapy to patients with clinical stage IIB seminoma and S1 disease  (<a class="graphic graphic_table graphicRef110731 graphicRef110732" href="/z/d/graphic/110731.html" rel="external">table 1A-B</a> and <a class="graphic graphic_algorithm graphicRef142688" href="/z/d/graphic/142688.html" rel="external">algorithm 1</a>). These tumors, which are classified as "good-risk" disease using the International Germ Cell Cancer Collaborative Group (IGCCCG) criteria  (<a class="graphic graphic_table graphicRef61906" href="/z/d/graphic/61906.html" rel="external">table 2</a>), are treated with either four cycles of EP  (<a class="graphic graphic_table graphicRef63222" href="/z/d/graphic/63222.html" rel="external">table 3</a>) or three cycles of BEP  (<a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">table 4</a>). Further details and data for this risk-stratified approach in advanced testicular GCTs are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'General approach to advanced disease'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Stage IIC seminoma</span><span class="headingEndMark"> — </span>For patients with clinical stage IIC seminoma, regardless of the absence or presence of postorchiectomy tumor marker status (S0 or S1), we recommend cisplatin-based chemotherapy rather than RT  (<a class="graphic graphic_algorithm graphicRef142688" href="/z/d/graphic/142688.html" rel="external">algorithm 1</a>), as chemotherapy is associated with a lower risk of disease relapse in this population. Options for chemotherapy regimens include three cycles of <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or four cycles of etoposide plus cisplatin. (See <a class="local">'Chemotherapy'</a> below.)</p><p>In observational studies of stage IIC seminoma, the risk of relapse with RT is approximately 20 percent or greater [<a href="#rid10">10,14</a>], and such patients would subsequently need systemic therapy. Although cisplatin-based chemotherapy can still successfully treat patients with bulky seminoma who relapse after prior RT, it may also be less effective after treatment with extensive RT compared with limited-field RT [<a href="#rid15">15,16</a>]. (See  <a class="medical medical_review" href="/z/d/html/2999.html" rel="external">"Diagnosis and treatment of relapsed and refractory testicular germ cell tumors"</a>.)</p><p>By contrast, seminoma is highly sensitive to chemotherapy. Clinical trials and observational studies have documented the favorable outcome in this population, with 90 percent of patients achieving long-term relapse-free survival. In a prospective observational study conducted by SWENOTECA, 42 males with stage IIC seminoma were treated with four cycles of <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid11">11</a>]. The five-year cancer-specific and overall survival rates were 97.6 and 95.1 percent, respectively; there were six relapses and three deaths due to progressive cancer. </p><p class="headingAnchor" id="H3235191095"><span class="h1">TREATMENT MODALITIES</span><span class="headingEndMark"> — </span>For patients with stage II seminoma, treatment options include cisplatin-based chemotherapy and radiation therapy (RT) to the retroperitoneal lymph nodes. </p><p class="headingAnchor" id="H1822617055"><span class="h2">Radiation therapy</span><span class="headingEndMark"> — </span>The total radiation dose to areas of gross adenopathy is 30 Gy for stage IIA seminoma and 36 Gy for stage IIB seminoma. Standard RT following orchiectomy for patients with stage IIA/stage IIB disease (see <a class="local">'Definition of stage II seminoma'</a> above) consists of low-dose treatment to the paraaortic lymph nodes and superior ipsilateral pelvis (20 to 25 Gy) followed by a cone down to the involved nodal areas [<a href="#rid17">17</a>]. </p><p>The "modified dog-leg" field has become the standard in stage II seminoma. A study conducted by the German Testicular Cancer Study Group (GTCSG) evaluated the "modified dog-leg" field where the inferior border of the RT field was placed at the top of the acetabulum. This field modification led to no increase in pelvic relapses [<a href="#rid9">9,18,19</a>]. </p><p>The scrotum, inguinal and lower pelvic lymph nodes, and mediastinum are not routinely treated with RT [<a href="#rid20">20</a>]. All patients should use a clamshell shield to reduce the radiation dose to the contralateral testicle [<a href="#rid20">20</a>]. A clamshell shield should also be used for patients who have completed sperm banking to preserve both spermatogenesis and testosterone production [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/2993.html" rel="external">"Treatment of stage I seminoma", section on 'Adjuvant radiation therapy'</a>.)</p><p>The toxicities of RT for stage II seminoma are similar to those seen with the treatment of stage I seminoma. Further details are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2993.html" rel="external">"Treatment of stage I seminoma", section on 'Adjuvant radiation therapy'</a>.)</p><p class="headingAnchor" id="H274606666"><span class="h2">Chemotherapy</span><span class="headingEndMark"> — </span>All patients with stage II seminoma, by definition, have disease limited to the lymph nodes and are classified as having good-risk disease by the International Germ Cell Cancer Collaborative Group (IGCCCG)  (<a class="graphic graphic_table graphicRef61906" href="/z/d/graphic/61906.html" rel="external">table 2</a>) [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Seminomas'</a>.)</p><p>Like other good-risk testicular germ cell tumors (GCTs), patients with stage II seminoma who are treated with chemotherapy can receive either three cycles of <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (BEP)  (<a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">table 4</a>) or four cycles of etoposide plus cisplatin (EP)  (<a class="graphic graphic_table graphicRef63222" href="/z/d/graphic/63222.html" rel="external">table 3</a>). Selecting between these regimens is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Seminomas'</a> and  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Good risk'</a>.)</p><p class="headingAnchor" id="H2887892606"><span class="h1">POSTTHERAPY RESIDUAL MASSES</span><span class="headingEndMark"> — </span>All patients with stage II seminoma who have completed treatment (either chemotherapy or radiation therapy [RT]) should undergo imaging to assess for posttherapy residual retroperitoneal masses. Imaging options include either contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI).</p><p>Patients with seminoma can have residual retroperitoneal masses on imaging following treatment, particularly those with bulky disease who received chemotherapy [<a href="#rid22">22,23</a>]. For such patients, management is based on the size of the residual disease, which is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/2952.html" rel="external">"Approach to surgery following chemotherapy for advanced testicular germ cell tumors", section on 'Seminoma'</a> and  <a class="medical medical_review" href="/z/d/html/2952.html" rel="external">"Approach to surgery following chemotherapy for advanced testicular germ cell tumors", section on 'Normalized tumor markers with abnormal imaging findings'</a>.)</p><p class="headingAnchor" id="H1892230862"><span class="h1">INVESTIGATIONAL APPROACHES</span><span class="headingEndMark"> — </span>It is important to reduce the risk of treatment toxicities in testicular cancer survivors. For patients with stage II seminoma, there are long-term toxicities associated with cisplatin-based chemotherapy regimens and radiation therapy. Various methods have been evaluated to reduce these toxicities, such as de-intensified chemotherapy, chemoradiation, and retroperitoneal lymph node dissection. These approaches remain investigational, and interested patients should be encouraged to enroll in clinical trials, where available.</p><p class="headingAnchor" id="H4002909350"><span class="h2">De-intensified chemotherapy</span><span class="headingEndMark"> — </span>The use of single-agent <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> is not established in stage II seminoma, as data are mixed for the efficacy and toxicity of this approach [<a href="#rid24">24-26</a>]. </p><p>Some studies have demonstrated high relapse rates with three to four cycles of single-agent <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> (AUC = 7) [<a href="#rid24">24</a>]. Randomized trials also suggest that single-agent carboplatin has inferior overall survival compared with cisplatin-based combination chemotherapy [<a href="#rid27">27</a>]. In contrast, other studies have demonstrated excellent outcomes for three to four cycles of single-agent carboplatin at higher doses (AUC = 10), including low relapse rates and five-year overall survival greater than 95 percent [<a href="#rid28">28</a>]. However, data are lacking for long-term toxicities and quality of life in this study. In addition, carboplatin resulted in significant hematologic toxicity, including the need for blood product transfusions.</p><p>There is interest in investigating risk-adapted strategies to de-intensify chemotherapy in patients with seminoma. In a non-randomized phase II trial (SEMITEP), 102 patients with good prognosis stage IIB/C or stage III seminoma were treated with two cycles of EP followed by an FDG-PET/CT scan to evaluate treatment response [<a href="#rid26">26</a>]. Patients with residual FDG-avid disease on PET-CT received two additional cycles of EP (EP x 4), whereas those with no residual FDG-avid disease received one additional cycle of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> (AUC = 7). In the entire study population, 67 patients (69 percent) had a negative FDG-PET/CT after two cycles of EP and proceeded to single-agent carboplatin. Patients who received two cycles of EP followed by single-agent carboplatin had similar progression-free survival (PFS) compared with those who received EP x 4 (three-year PFS of 91 and 90 percent, respectively) with lower rates of peripheral neuropathy and ototoxicity. </p><p class="headingAnchor" id="H95687233"><span class="h2">Chemoradiation</span><span class="headingEndMark"> — </span>The sequential use of chemotherapy and radiation remains investigational in stage II seminoma, and further long-term follow-up on outcomes and toxicities is necessary. </p><p>In a phase II trial (SAKK 01/10), 116 patients with stage IIA/B seminoma were treated with one cycle of single-agent <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> (AUC = 7) followed by RT to the involved regional lymph nodes [<a href="#rid25">25</a>]. RT administered to the lymph nodes was expanded by 3 cm in craniocaudal dimension and 2 cm in axial dimensions, which differs from the typical "modified dog-leg" field used to treat stage II seminoma. (See <a class="local">'Radiation therapy'</a> above.) </p><p>At median follow-up of 4.5 years, the three-year progression-free survival (PFS) was 93.7 percent in the entire population, narrowly missing the prespecified primary endpoint [<a href="#rid25">25</a>]. In addition, the incidence of late toxicities is unknown for this approach. Prior studies have demonstrated greater risks of secondary malignancies and cardiovascular disease among patients treated with radiation and chemotherapy as compared with either modality alone [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H3900606040"><span class="h2">Retroperitoneal lymph node dissection</span><span class="headingEndMark"> — </span>Retroperitoneal lymph node dissection (RPLND) has been investigated in stage II seminoma as a potential method of avoiding the long-term sequelae of radiation and chemotherapy [<a href="#rid29">29-31</a>]. This approach remains investigational, as data from clinical trials have been mixed for its efficacy [<a href="#rid5">5,32</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>In a single-arm phase II trial (Surgery in Early Metastatic Seminoma; SEMS), 55 patients with testicular seminoma and isolated retroperitoneal lymphadenopathy (no larger than 3 cm) were treated with an open modified template RPLND [<a href="#rid5">5</a>]. The median sizes of the largest clinical and pathologic (post-RPLND) lymph nodes were 1.6 and 2.3 cm, respectively. The rates of pathologic N0, N1, N2, and N3 disease were 16, 22, 56, and 5 percent, respectively. At median follow-up of 33 months, two-year recurrence-free survival was 81 percent [<a href="#rid5">5</a>]. Recurrences were seen in 12 patients (22 percent) who were treated with chemotherapy (10 patients) or additional surgery (2 patients). All patients with recurrences were disease-free at follow-up, and the two-year overall survival was 100 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, a similar study (PRIMETEST) demonstrated a higher risk of recurrence with RPLND (30 percent) in stage IIA/B seminoma, which did not meet the prespecified study endpoint [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H2170354322"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122274.html" rel="external">"Society guideline links: Testicular cancer"</a>.)</p><p class="headingAnchor" id="H2175763232"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15502.html" rel="external">"Patient education: Testicular cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/863.html" rel="external">"Patient education: Testicular cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Patients with clinical stage II seminoma have pure seminoma in their orchiectomy specimen and imaging studies that suggest the disease is limited to the regional (retroperitoneal) lymph nodes. Postorchiectomy tumor markers can either be within normal limits (ie, S0) or elevated within a specific range (S1)  (<a class="graphic graphic_table graphicRef110731 graphicRef110732" href="/z/d/graphic/110731.html" rel="external">table 1A-B</a> and <a class="graphic graphic_algorithm graphicRef142688" href="/z/d/graphic/142688.html" rel="external">algorithm 1</a>). (See <a class="local">'Definition of stage II seminoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical stage IIA seminoma</strong> <strong>(S0)</strong> – The treatment of patients with clinical stage IIA seminoma (S0) is as follows (see <a class="local">'Stage IIA seminoma (S0)'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Borderline enlarged lymph nodes</strong> – For patients with borderline enlarged retroperitoneal lymph nodes (approximately 1 cm in greatest dimension), we observe for six to eight weeks, then repeat imaging. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Lymph nodes that decrease in size to less than 1 cm are likely benign. Such patients can continue surveillance or be treated like those with stage I seminoma. (See  <a class="medical medical_review" href="/z/d/html/2993.html" rel="external">"Treatment of stage I seminoma"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients whose lymph nodes increase in size on repeat imaging can be treated for stage II seminoma. (See <a class="local">'Borderline lymph nodes (1 cm)'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients whose lymph nodes remain stable in size can continue imaging surveillance, which allows time to determine the etiology of the nodes (benign or malignant) and the appropriate treatment strategy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lymph nodes between 1 and 2 cm</strong> – For those with enlarged retroperitoneal lymph nodes between 1 cm and 2 cm in greatest dimension, treatment options include either radiation therapy (RT) or cisplatin-based chemotherapy. (See <a class="local">'Lymph nodes between 1 and 2 cm'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with larger (closer to 2 cm) or more numerous lymph nodes (especially those distributed over a large area of the retroperitoneum) may derive greater benefit from chemotherapy over RT, extrapolating from data in more advanced stage tumors. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>However, RT is associated with less acute toxicity and shorter duration of therapy, and may be preferable for some patients, particularly those with smaller lymph nodes. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Long-term toxicity profiles differ between these modalities and should be discussed with the patient. For example, RT is associated with second malignancies (especially in those who relapse and require subsequent chemotherapy), while chemotherapy is associated with cardiac disease, neuropathy, tinnitus, and infertility, among other toxicities. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical stage IIB seminoma (S0)</strong> – For most patients with clinical stage IIB seminoma (S0), we suggest cisplatin-based combination chemotherapy rather than RT (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). RT is an alternative for stage IIB seminoma with lymph nodes ≤3 cm. (See <a class="local">'Stage IIB seminoma (S0)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical stage IIA/B seminoma (S1)</strong> – We offer cisplatin-based chemotherapy to patients with either clinical stage IIA (S1) or stage IIB (S1) seminoma  (<a class="graphic graphic_table graphicRef63222" href="/z/d/graphic/63222.html" rel="external">table 3</a>), as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Good risk'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical stage IIC seminoma</strong> – For patients with clinical stage IIC seminoma, regardless of postorchiectomy tumor marker status (S0 or S1), we suggest cisplatin-based chemotherapy rather than RT (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Stage IIC seminoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment modalities </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cisplatin-based combination chemotherapy </strong>– When chemotherapy is chosen for stage II seminoma, options include either three cycles of <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (BEP)  (<a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">table 4</a>) or four cycles of etoposide plus cisplatin (EP)  (<a class="graphic graphic_table graphicRef63222" href="/z/d/graphic/63222.html" rel="external">table 3</a>). Selecting between these regimens is discussed separately. (See <a class="local">'Chemotherapy'</a> above and  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Good risk'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Radiation therapy</strong> – For those treated with RT, the total radiation dose to areas of gross adenopathy is 30 Gy for stage IIA seminoma and 36 Gy for stage IIB seminoma. (See <a class="local">'Radiation therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Residual retroperitoneal mass</strong> – For patients with stage II seminoma and residual retroperitoneal masses after treatment completion, the management is dependent on the size of the residual disease, as discussed separately. (See <a class="local">'Posttherapy residual masses'</a> above and  <a class="medical medical_review" href="/z/d/html/2952.html" rel="external">"Approach to surgery following chemotherapy for advanced testicular germ cell tumors"</a>.)</p><p></p><p class="headingAnchor" id="H436333897"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Clair J Beard, MD, and William K Oh, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kollmannsberger C, Tyldesley S, Moore C, et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol 2011; 22:808.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN) guidelines: Testicular cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf (Accessed on April 05, 2023).</li><li><a class="nounderline abstract_t">Oldenburg J, Berney DM, Bokemeyer C, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33:362.</a></li><li><a class="nounderline abstract_t">Hamilton RJ, Canil C, Shrem NS, et al. Canadian Urological Association consensus guideline: Management of testicular germ cell cancer. Can Urol Assoc J 2022; 16:155.</a></li><li><a class="nounderline abstract_t">Daneshmand S, Cary C, Masterson T, et al. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol 2023; 41:3009.</a></li><li><a class="nounderline abstract_t">van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007; 25:4370.</a></li><li><a class="nounderline abstract_t">Giannatempo P, Greco T, Mariani L, et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann Oncol 2015; 26:657.</a></li><li><a class="nounderline abstract_t">Heinzelbecker J, Schmidt S, Lackner J, et al. Therapy of clinical stage IIA and IIB seminoma: a systematic review. World J Urol 2022; 40:2829.</a></li><li><a class="nounderline abstract_t">Classen J, Schmidberger H, Meisner C, et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003; 21:1101.</a></li><li><a class="nounderline abstract_t">Chung PW, Gospodarowicz MK, Panzarella T, et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 2004; 45:754.</a></li><li><a class="nounderline abstract_t">Tandstad T, Smaaland R, Solberg A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol 2011; 29:719.</a></li><li><a class="nounderline abstract_t">Garcia-del-Muro X, Maroto P, Gumà J, et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol 2008; 26:5416.</a></li><li><a class="nounderline abstract_t">Fung C, Dinh P Jr, Ardeshir-Rouhani-Fard S, et al. Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors. Adv Urol 2018; 2018:8671832.</a></li><li><a class="nounderline abstract_t">Hallemeier CL, Pisansky TM, Davis BJ, Choo R. Long-term outcomes of radiotherapy for stage II testicular seminoma--the Mayo Clinic experience. Urol Oncol 2013; 31:1832.</a></li><li><a class="nounderline abstract_t">Fosså SD, Borge L, Aass N, et al. The treatment of advanced metastatic seminoma: experience in 55 cases. J Clin Oncol 1987; 5:1071.</a></li><li><a class="nounderline abstract_t">Loehrer PJ Sr, Birch R, Williams SD, et al. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 1987; 5:1212.</a></li><li><a class="nounderline abstract_t">Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15:1377.</a></li><li><a class="nounderline abstract_t">Bamberg M, Schmidberger H, Meisner C, et al. Radiotherapy for stages I and IIA/B testicular seminoma. Int J Cancer 1999; 83:823.</a></li><li><a class="nounderline abstract_t">Schmidberger H, Bamberg M, Meisner C, et al. Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int J Radiat Oncol Biol Phys 1997; 39:321.</a></li><li><a class="nounderline abstract_t">Wilder RB, Buyyounouski MK, Efstathiou JA, Beard CJ. Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biol Phys 2012; 83:e445.</a></li><li><a class="nounderline abstract_t">International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15:594.</a></li><li><a class="nounderline abstract_t">Abratt RP, McAdam GL, Pontin AR, et al. Primary chemotherapy for stage 2 testis cancer. S Afr J Surg 1997; 35:203.</a></li><li><a class="nounderline abstract_t">Peckham MJ, Horwich A, Hendry WF. Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Br J Cancer 1985; 52:7.</a></li><li><a class="nounderline abstract_t">Krege S, Boergermann C, Baschek R, et al. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol 2006; 17:276.</a></li><li><a class="nounderline abstract_t">Papachristofilou A, Bedke J, Hayoz S, et al. Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022; 23:1441.</a></li><li><a class="nounderline abstract_t">Loriot Y, Texier M, Culine S, et al. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Eur Urol 2022; 82:172.</a></li><li><a class="nounderline abstract_t">Bokemeyer C, Kollmannsberger C, Stenning S, et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer 2004; 91:683.</a></li><li><a class="nounderline abstract_t">Alifrangis C, Sharma A, Chowdhury S, et al. Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients. Eur J Cancer 2022; 164:105.</a></li><li><a class="nounderline abstract_t">Alsyouf M, Daneshmand S. Intricacies of retroperitoneal lymph node dissection for testis cancer. Curr Opin Urol 2022; 32:24.</a></li><li><a class="nounderline abstract_t">Hu B, Daneshmand S. Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma. Adv Urol 2018; 2018:7978958.</a></li><li><a class="nounderline abstract_t">Tachibana I, Alabd A, Tong Y, et al. Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward? J Clin Oncol 2023; 41:3930.</a></li><li><a class="nounderline abstract_t">Hiester A, Che Y, Lusch A, et al. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). Eur Urol 2023; 84:25.</a></li></ol></div><div id="topicVersionRevision">Topic 2990 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926549" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926549" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35065204" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35623007" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Canadian Urological Association consensus guideline: Management of testicular germ cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36913642" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17906202" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25214543" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34779882" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Therapy of clinical stage IIA and IIB seminoma: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637477" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15149748" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Stage II testicular seminoma: patterns of recurrence and outcome of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21205748" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936476" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29670654" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22537538" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Long-term outcomes of radiotherapy for stage II testicular seminoma--the Mayo Clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2439660" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The treatment of advanced metastatic seminoma: experience in 55 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2442317" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15319245" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10597202" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Radiotherapy for stages I and IIA/B testicular seminoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9308934" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22436787" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Radiotherapy treatment planning for testicular seminoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9053482" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9540399" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Primary chemotherapy for stage 2 testis cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3893507" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254023" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36228644" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35599187" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15266338" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33041185" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34698701" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Intricacies of retroperitoneal lymph node dissection for testis cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29487620" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36730902" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36372627" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST).</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
